The Forum for Collaborative HIV Research

Announcements

Bi-Partisan Congressional Briefing: Combating Viral Hepatitis

MAY-17-12 A bi-partisan Congressional briefing will take place next week entitled, "Combating Viral Hepatitis: 2012 Hepatitis Testing Day and the One-Year Anniversary on U.S. Department of Health and Human Services Action Plan for the Prevention and Treatment of Viral Hepatitis." The briefing will be held on Thursday, May 17 from 9-10:30 AM in 2237 Rayburn House Office Building. Please note the time change. Read more.

Forum now Hiring Deputy Director

MAY-11-12 The Forum for Collaborative HIV Research currently seeks applicants for Deputy Director. This position oversees a moderately sized research program entitled the Forum for Collaborative HIV Research located in Washington D.C., represents the program to outside organizations to meet scientific goals and objectives set by the Director. The Deputy Director also is responsible for recruiting and retaining industrial leaders to partner with research program in achievement of Forum goals, and develops and manages a membership program for industry partners. Click here to read more.

CDC Releases Division of HIV/AIDS Prevention's Annual Report

MAY-04-12 The Division of HIV/AIDS Prevention (DHAP) recently released its annual report, Accelerating Progress, Investing for Impact, which provides an overview of some of the HIV prevention activities conducted and supported by the CDC from late 2010 to the end of 2011. Click here to access the report.

FDA Blood Products Advisory Committee to Meet May 15-16

MAY-15/16-12 The U.S. Food and Drug Administration (FDA) Blood Products Advisory Committee (BPAC) will meet on May 15th and 16th on a variety of topics including OraSure's application for approval of its OTC rapid HIV test and the evaluation of possible frozen plasma products. Read more.

HCV DrAG Presents Poster at EASL 2012

MAY-02-12 The Hepatitis C Drug Development Advisory Group's (HCV DrAG) Definitions and Nomenclature Working Group (DNWG) presented a poster titled "Consensus Recommendations for Virologic Nomenclature in DAA Clinical Trials" at the 2012 European Association for the Study of the Liver (EASL) meeting in Barcelona, Spain. Read more.

FDA Advisory Committee Meetings May 10-11

MAY-10/11-12 The Food and Drug Administration (FDA) Antiviral Drugs Advisory Committee will convene two separate meetings on May 10th and 11th, 2012 to review two submissions from Gilead Sciences, Inc. Read more.

NVHR Congressional Letter of Support for Viral Hepatitis Testing Act

MAY-02-12 Please join NVHR in signing the attached letter of support and thanks to champions in Congress for introducing the Viral Hepatitis Testing Act. NVHR would like to deliver this letter on the occasion of the first viral hepatitis testing day on May 19th. The letter will also serve to educate members of Congress about the Act and encourage them to add their names to the list of co-sponsors. Read more.

Current Projects

Home

Overcoming Health Disparities in the Bay Area - Using HIV/AIDS as a Model

MAY-23/24-2012 Despite major advances in the areas of treatment and prevention of HIV/AIDS, health disparities persist and manifest in different ways. The workshop will provide a mechanism to (1) capture what interventions are being researched within academic centers, community organizations and other research venues; (2) strengthen community research by providing assistance with evaluation as needed; (3) set the framework for developing a research agenda of new interventions; (4) help solidify the science of disparities and its interventions.

CLICK HERE FOR THE OFFICIAL MEETING ANNOUNCEMENT

CLICK HERE TO REGISTER FOR THE WORKSHOP! Click "Read more" below for important fee and scholarship information. Registration fee includes access to all sessions, lunch both days, dinner reception the evening of the 23rd and printed materials.

Featuring a special performance from the Medea Project: Theatre for Incarcerated Women/ The HIV Circle

Pat Mazzera/Cultural Odyssey

HCV Drug ResisSS 2012 v.1

JAN-30-12 UPDATED: Recognizing the need for education regarding HCV drug resistance, the Forum for Collaborative HIV Research's HCV Drug Development Advisory Group (academicians, clinicians, researchers and patient advocates) have contributed to a slide deck explaining resistance in HCV, its consequences as well as its mitigation.
Read more...

HCV Trials in the Post-Approval Era of Telaprevir and Boceprevir - The Way Forward

OCT-18-11 The October 18, 2011 meeting sponsored by the Forum was designed to facilitate consensus on issues with the choice of control arm in HCV trials and was attended by representatives from regulatory agencies (US, EMA, Health Canada), NIH, academia, pharmaceutical companies, and patient advocates.
Read more...

HCV DrAG Meeting #7: Issues in HCV Clinical Trials

NOV-03-11 On November 3rd, the Forum held the 7th HCV DrAG Meeting in San Francisco, in conjunction with the 62nd American Association for the Study of Liver Diseases (AASLD) meeting "Issues in HCV Clinical Trials" focused on HCV viral load assays (LOD/LLOQ), as well as trials in current drug users and patients on opiate substitution therapy. With 72 people in attendance representing regulatory agencies, industry, academia, treatment, and advocacy, the panels had lively and productive discussions. In addition to spurring interest in special populations such as bleeding disorder and opiate substitution patients, the seventh HCV DrAG Meeting appears to have brought consensus on the HCV viral load cut-off and reporting, both of which will be used in trials and will translate into practice.

Join Our Email Service

Announcements